

# Accepted Manuscript

DOCK8-Deficient CD4<sup>+</sup> T Cells are Biased to a Th2 Effector Fate at the Expense of Th1 and Th17 Cells

Stuart G. Tangye, PhD, Bethany Pillay, BSc Hons, Katrina L. Randall, MBBS, PhD, FRACP, FRCPA, Danielle T. Avery, BAppSci, Tri Giang Phan, MBBS, PhD, FRACP, FRCPA, Paul Gray, FRACP, John B. Ziegler, MD, FRACP, Joanne M. Smart, MBBS, FRACP, Jane Peake, MBBS, Peter D. Arkwright, FRCPCH, DPhil, Sophie Hambleton, DPhil, Jordan Orange, MD, PhD, Christopher C. Goodnow, PhD, Gulbu Uzel, MD, Jean-Laurent Casanova, MD, PhD, Saul Oswaldo Lugo Reyes, MD, Alexandra F. Freeman, MD, Helen C. Su, MD, PhD, Cindy S. Ma, PhD

PII: S0091-6749(16)30798-9

DOI: [10.1016/j.jaci.2016.07.016](https://doi.org/10.1016/j.jaci.2016.07.016)

Reference: YMAI 12288

To appear in: *Journal of Allergy and Clinical Immunology*


Received Date: 8 February 2016

Revised Date: 1 July 2016

Accepted Date: 12 July 2016

Please cite this article as: Tangye SG, Pillay B, Randall KL, Avery DT, Phan TG, Gray P, Ziegler JB, Smart JM, Peake J, Arkwright PD, Hambleton S, Orange J, Goodnow CC, Uzel G, Casanova J-L, Lugo Reyes SO, Freeman AF, Su HC, Ma CS, DOCK8-Deficient CD4<sup>+</sup> T Cells are Biased to a Th2 Effector Fate at the Expense of Th1 and Th17 Cells, *Journal of Allergy and Clinical Immunology* (2016), doi: [10.1016/j.jaci.2016.07.016](https://doi.org/10.1016/j.jaci.2016.07.016).

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **DOCK8-DEFICIENT CD4<sup>+</sup> T CELLS ARE BIASED TO A TH2 EFFECTOR FATE AT**  
2 **THE EXPENSE OF TH1 AND TH17 CELLS.**

3  
4 Stuart G Tangye, PhD,<sup>1,2</sup> Bethany Pillay BSc Hons,<sup>1,2</sup> Katrina L Randall, MBBS, PhD, FRACP,  
5 FRCPA,<sup>3,4</sup> Danielle T Avery, BApplSci,<sup>1</sup> Tri Giang Phan, MBBS, PhD, FRACP, FRCPA,<sup>1,2</sup>  
6 Paul Gray, FRACP,<sup>5</sup> John B Ziegler, MD, FRACP,<sup>5</sup> Joanne M Smart, MBBS, FRACP,<sup>6</sup> Jane  
7 Peake, MBBS,<sup>7</sup> Peter D Arkwright, FRCPCH, DPhil,<sup>8</sup> Sophie Hambleton, DPhil,<sup>9</sup> Jordan  
8 Orange, MD, PhD,<sup>10</sup> Christopher C. Goodnow, PhD,<sup>1,2</sup> Gulbu Uzel, MD,<sup>11</sup> Jean-Laurent  
9 Casanova, MD, PhD,<sup>12,13,14,15</sup> Saul Oswaldo Lugo Reyes, MD,<sup>16</sup> Alexandra F. Freeman, MD,<sup>11</sup>  
10 Helen C Su, MD, PhD,<sup>17</sup> and Cindy S Ma, PhD,<sup>1,2</sup>.

11  
12 <sup>1</sup>Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia;

13 <sup>2</sup>St Vincent's Clinical School, UNSW Australia;

14 <sup>3</sup>Department of Immunology, The John Curtin School of Medical Research, Acton, Australian Capital  
15 Territory, Australia;

16 <sup>4</sup>Australian National University Medical School, Australian National University, Acton, Australian  
17 Capital Territory, Australia;

18 <sup>5</sup>University of New South Wales School of Women's and Children's Health, NSW, Australia;

19 <sup>6</sup>Department of Allergy and Immunology, Royal Children's Hospital Melbourne, VIC, Australia;

20 <sup>7</sup>University of Queensland and Lady Cilento Children's Hospital, Brisbane, QLD 4006, Australia;

21 <sup>8</sup>University of Manchester, Royal Manchester Children's Hospital, Manchester M13 9WL, UK;

22 <sup>9</sup>Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle  
23 upon Tyne, NE4 6BE, UK;

24 <sup>10</sup>Texas Children's Hospital Center for Human Immunobiology, Houston, TX, USA;

25 <sup>11</sup>Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA;

26 <sup>12</sup>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Institut  
27 IMAGINE, Necker Medical School, University Paris Descartes, Paris, France;

28 <sup>13</sup>Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, AP-HP, Paris,  
29 France;

30 <sup>14</sup>St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller  
31 University, New York, USA;

32 <sup>15</sup>Howard Hughes Medical Institute, NY, USA;

33 <sup>16</sup>Immunodeficiencies Research Unit, National Institute of Pediatrics, Mexico City 04530, Mexico;

34 <sup>17</sup>Laboratory of Host Defenses, NIAID, NIH, Bethesda, Maryland, USA.

35  
36  
37 **Corresponding authors**

38 Professor Stuart Tangye; Dr Cindy Ma

39 Immunology Division

40 Garvan Institute of Medical Research

41 384 Victoria St, Darlinghurst. NSW. 2010 Australia

42 Phone: +61 2 9295 8455; Fax: +61 2 9295 8404

43 e-mail: s.tangye@garvan.org.au; c.ma@garvan.org.au

44 **ABSTRACT**

45 **Background:** Deducator of cytokinesis 8 (DOCK8) deficiency is a combined  
46 immunodeficiency caused by autosomal recessive loss-of-function mutations in *DOCK8*. This  
47 disorder is characterised by recurrent cutaneous infections, elevated serum IgE, and severe  
48 atopic disease including anaphylaxis to foods. However, the contribution of defects in CD4<sup>+</sup> T  
49 cells to disease pathogenesis in these patients has not been thoroughly investigated.

50 **Objective:** To investigate the phenotype and function of DOCK8-deficient CD4<sup>+</sup> T cells to  
51 determine (1) intrinsic and extrinsic CD4<sup>+</sup> T cell defects (2) how defects account for the clinical  
52 features of DOCK8 deficiency.

53 **Methods:** We performed indepth analysis of the CD4<sup>+</sup> T cell compartment of DOCK8-deficient  
54 patients. We enumerated subsets of CD4<sup>+</sup> T helper cells and assessed cytokine production and  
55 transcription factor expression. Finally, we determined the levels of IgE specific for staple  
56 foods and house dust mite allergens in DOCK8-deficient patients and normal controls.

57 **Results:** DOCK8-deficient memory CD4<sup>+</sup> T cells were biased towards a Th2 type, and this was  
58 at the expense of Th1 and Th17 cells. *In vitro* polarisation of DOCK8-deficient naive CD4<sup>+</sup> T  
59 cells revealed the Th2 bias and Th17 defect to be T-cell intrinsic. Examination of allergen  
60 specific IgE revealed plasma IgE from DOCK8-deficient patients is directed against staple food  
61 antigens, but not house dust mites.

62 **Conclusion:** Investigations into the DOCK8-deficient CD4<sup>+</sup> T cells provided an explanation for  
63 some of the clinical signs of this disorder - the Th2 bias is likely to contribute to atopic disease,  
64 while defects in Th1 and Th17 cells compromise anti-viral and anti-fungal immunity,  
65 respectively explaining the infectious susceptibility of DOCK8-deficient patients.

66

**67 KEY MESSAGES**

- 68 • DOCK8-deficient CD4<sup>+</sup> T cells present with a Th2 cytokine bias, but also defects in  
69 Th1 and Th17 cells
- 70 • The Th2 cytokine bias by DOCK8-deficient cells contributes to atopic disease such as  
71 eczema and food allergies in DOCK8 deficiency
- 72 • Th17 cell defect is T cell intrinsic and contributes to compromised anti-fungal immunity  
73 in DOCK8-deficient patients.

**74**  
**75 CAPSULE SUMMARY**

76 DOCK8-deficient CD4<sup>+</sup> T cells exhibit dysregulated cytokine responses, with exaggerated  
77 production of Th2 cytokines, and impaired production of Th1 and Th17 cytokines. Collectively  
78 these findings provide explanations for some of the clinical features of DOCK8 deficiency,  
79 such as eczema and food allergies, and recurrent viral and microbial infections.

80  
81 **KEYWORDS:** Deducator of cytokinesis 8, CD4<sup>+</sup> T cell differentiation, Th2 skewing, allergy,  
82 atopic disease, chronic mucocutaneous candidiasis, viral immunity

**83**  
**84 ABBREVIATIONS USED:**

85 AR-HIES: autosomal recessive hyper IgE syndrome  
86 BCG: Bacille Calmette-Guerin  
87 CMC: chronic mucocutaneous candidiasis  
88 CMV: cytomegalovirus  
89 DOCK8: Deducator of cytokinesis 8  
90 EBV: Epstein-Barr virus  
91 HHV6: human herpes virus 6  
92 HPV: human papilloma virus  
93 HSCT: Hematopoietic stem cell transplant  
94 HSV: herpes simplex virus  
95 STAT: signal transducer and activator of transcription  
96 TAE: T cell activation and expansion  
97 T<sub>CM</sub>: central memory T cell  
98 TCR: T cell receptor  
99 T<sub>EM</sub>: effector memory T cell

- 100 Tfh: T follicular helper  
101 Tregs: regulatory T cells  
102 VZV: Varicella-zoster virus  
103 XLP: X-linked lymphoproliferative disease  
104  
105

ACCEPTED MANUSCRIPT

106 **INTRODUCTION**

107 Bi-allelic loss-of-function mutations in dedicator of cytokinesis 8 (*DOCK8*) cause a combined  
108 immunodeficiency also known as an autosomal recessive form of hyper IgE syndrome (AR-  
109 HIES)<sup>1, 2</sup>. Affected patients typically present with recurrent *Staphylococcus aureus* skin  
110 infections, recurrent and severe cutaneous viral infections (HSV, HPV, *Molluscum contagiosum*  
111 virus), elevated serum IgE levels, lymphopenia, eosinophilia and an increased risk of  
112 malignancy<sup>1-3</sup>. *DOCK8*-deficient patients also exhibit impaired humoral immune responses  
113 against protein and polysaccharide antigens following natural infection or vaccination.  
114 Strikingly, *DOCK8* deficiency predisposes most affected patients to developing asthma and  
115 severe allergies against food and environmental antigens<sup>1-5</sup>. However, the mechanisms  
116 underlying severe allergy are currently unknown.

117  
118 *DOCK8* functions as a guanine nucleotide exchange factor to activate Rho-family GTPases  
119 such as CDC42, which mediate events including cell activation, division, survival,  
120 differentiation, adhesion, and migration<sup>6-8</sup>. Despite this, it is not immediately clear how *DOCK8*  
121 mutations result in the devastating immune abnormalities characteristic of patients with AR-  
122 HIES. However, as *DOCK8* is predominantly expressed by hematopoietic cells, it is likely to  
123 play critical lymphocyte-intrinsic roles in cellular and humoral immune responses against  
124 infectious diseases. Consistent with this, allogeneic hematopoietic stem cell transplant (HSCT)  
125 overcomes recurrent cutaneous viral infections, eczematous rash, and reduces IgE levels and  
126 eosinophilia<sup>9-14</sup>. In regards to food allergies in *DOCK8* deficiency, some reports have  
127 documented improvement post-HSCT<sup>10, 11, 14</sup>, while others reported amelioration to symptoms<sup>13</sup>  
128 or no change<sup>9, 15</sup>.

129  
130 *Ex vivo* and *in vitro* analyses of lymphocytes from *DOCK8*-deficient patients have shed some  
131 light on disease pathogenesis. For instance, *DOCK8*-deficient patients have normal to increased  
132 numbers of total B cells but decreased circulating memory (CD27<sup>+</sup>) B cells<sup>5, 16</sup>. Functionally,  
133 compared with normal B cells, *DOCK8*-deficient B cells exhibit poor responses to the TLR9  
134 ligand CpG, while CD40-mediated responses were largely intact<sup>5</sup>. In B cells, *DOCK8* acts as an  
135 adaptor protein connecting the TLR9-MYD88 pathway to STAT3 signalling, which is required  
136 for B cell proliferation and differentiation, as evidenced by defective function of STAT3-  
137 deficient human B cells *in vivo* and *in vitro*<sup>17-20</sup>. These defects underlie poor humoral immunity  
138 in *DOCK8*-deficiency. Paradoxically, an increase in autoantibodies directed against nuclear,

139 cytoplasmic and extracellular matrix antigens has been detected in DOCK8-deficient patients,  
140 possibly due to decreased regulatory T cells (Tregs) in these patients<sup>21</sup>.

141  
142 Our previous study of T cells in DOCK8-deficient individuals revealed a severe reduction in  
143 naïve, central memory (CD45RA<sup>-</sup>CCR7<sup>+</sup>) and effector memory (CD45RA<sup>-</sup>CCR7<sup>-</sup>) CD8<sup>+</sup> T  
144 cells but a marked accumulation of CD45RA<sup>+</sup>CCR7<sup>-</sup> terminally differentiated (i.e. “exhausted”)  
145 effector memory cells<sup>22</sup>. Strikingly, central and effector memory CD8<sup>+</sup> T cells from DOCK8-  
146 deficient individuals displayed phenotypic features of exhaustion, with increased expression of  
147 CD57, 2B4 and CD95, and accelerated loss of CD28 and CD127 (IL-7R $\alpha$ )<sup>22</sup>. Furthermore,  
148 DOCK8-deficient naïve and memory CD8<sup>+</sup> T cells failed to proliferate *in vitro* in response to T  
149 cell receptor (TCR) stimulation<sup>22</sup>. More recently, DOCK8-deficient CD8<sup>+</sup> T cells were reported  
150 to undergo “cytothripsis”, a form of cell death associated with defects in morphology and  
151 trafficking that prevented the generation of long-lived resident memory CD8<sup>+</sup> T cells in the skin  
152 and subsequently impaired immune responses to herpes virus infection at this site<sup>23</sup>. Taken  
153 together, these defects in CD8<sup>+</sup> T cells provide a plausible explanation for viral susceptibility in  
154 DOCK8-deficient patients. DOCK8-deficient patients also have defects in the development of  
155 NKT cells and function of NK cells<sup>24, 25</sup> which may contribute to increased susceptibility to  
156 viral infections and malignancies.

157  
158 In contrast to these established defects in B cells, Tregs, CD8<sup>+</sup> T cells, NK cells and NKT cells,  
159 much less is known about the consequences of *DOCK8* mutations in other human CD4<sup>+</sup> T  
160 helper cells. While it has been reported that the frequencies of naïve and memory CD4<sup>+</sup> T cells  
161 in DOCK8-deficient patients are normal, DOCK8-deficient naïve and memory CD4<sup>+</sup> T cells do  
162 have a defect in TCR-induced proliferation, albeit less severe than DOCK8-deficient CD8<sup>+</sup> T  
163 cells<sup>22</sup>. Consequently, this deficit is unlikely to cause clinical features such as atopic disease  
164 (dermatitis, severe food allergies) and increased IgE in DOCK8 deficiency. For this reason, we  
165 have undertaken a detailed analysis of the CD4<sup>+</sup> T cell compartment in DOCK8-deficient  
166 patients. We found that DOCK8-deficient memory CD4<sup>+</sup> T cells have a bias towards Th2  
167 cytokine expression (ie IL-4, IL-5, IL-13) and concomitant defective production of Th1 (IFN $\gamma$ )  
168 and Th17 (IL-17A, IL-17F, IL-22) cytokines. Furthermore, the Th2 cytokine bias and impaired  
169 Th17 immunity, in the absence of DOCK8 were T cell intrinsic and independent of defects in  
170 proliferation. This intrinsic Th2 bias of DOCK8-deficient CD4<sup>+</sup> T cells may underlie atopic  
171 disease and hyper-IgE displayed by DOCK8-deficient patients. Additionally, impaired Th1 and

172 Th17 responses likely account for impaired viral immunity and fungal infections such as  
173 chronic mucocutaneous candidiasis, respectively in DOCK8-deficient patients.

174

## 175 **METHODS**

### 176 **Human samples**

177 PBMCs and/or plasma were isolated from normal donors (Australian Red Cross) and patients  
178 with DOCK8 deficiency (Table 1). The genotype of some of these patients has been previously  
179 reported<sup>1, 2, 15, 22, 24</sup>. All studies were approved by Institutional Human Research Ethics  
180 Committees and written informed consent was obtained from patients.

181

### 182 **Antibodies and Reagents**

183 Alexa488-anti-GATA3, Alexa647-anti-CXCR5, APC-Cy7-anti-CD4, BUV395-anti-IFN $\gamma$ ,  
184 BV711-anti-CD69, BV711-anti-IL-2, PE-anti-CCR6, PE-anti-CD95, Pe-Cy7-anti-CD25, and  
185 anti-mouse IgG1, and PerCpCy5.5-anti-CD127 and anti-Tbet were from Becton Dickinson.  
186 Alexa488-anti-IL-10, APC-anti-ICOS, eFluor660-anti-IL-21, FITC-anti-CD45RA, PE-IL-22,  
187 Pe-Cy7-anti-IL-4 and mouse IgG1 were from eBiosciences. APC-Cy7-anti-IL-17A, BV421-  
188 anti-CXCR3, and BV605-anti-TNF $\alpha$  were from Biolegend. FITC-anti-CCR7 and recombinant  
189 human IL-12 was from R&D Systems. Anti-DOCK8 mAb was from Santa Cruz  
190 Biotechnology. Recombinant human TGF $\beta$ , IL-1 $\beta$ , IL-6, IL-21 and IL-23 were from Peprotech.  
191 Prostaglandin E2, PMA, calcium ionophore (ionomycin), Brefeldin A, and saponin were  
192 purchased from Sigma-Aldrich. Recombinant human IL-4 was provided by Dr Rene de Waal  
193 Malefyt (DNAX Research Institute, Palo Alto, CA). T cell activation and expansion (TAE)  
194 beads (anti-CD2/CD3/CD28) were purchased from Miltenyi Biotec and CFSE was purchased  
195 from Invitrogen.

196

### 197 **CD4<sup>+</sup> T cell phenotyping**

198 To identify naïve, central memory (T<sub>CM</sub>) and effector memory (T<sub>EM</sub>) CD4<sup>+</sup> T cell populations,  
199 PBMCs were incubated with mAbs to CD4, CCR7 and CD45RA and the frequency of  
200 CD4<sup>+</sup>CCR7<sup>+</sup>CD45RA<sup>+</sup> (naïve), CD4<sup>+</sup>CCR7<sup>+</sup>CD45RA<sup>-</sup> (T<sub>CM</sub>), and CD4<sup>+</sup>CCR7<sup>-</sup>CD45RA<sup>-</sup> (T<sub>EM</sub>)  
201 populations determined by flow cytometry. To identify CD4<sup>+</sup> T cell populations, PBMCs were  
202 incubated with mAbs to CD4, CD25, CD127, CXCR5, CD45RA, CCR6 and CXCR3, and the  
203 frequency of Tregs (CD4<sup>+</sup>CD25<sup>hi</sup>CD127<sup>lo</sup>), Tfh (CD4<sup>+</sup>CD25<sup>lo</sup>CD127<sup>hi</sup>CD45RA<sup>-</sup>CXCR5<sup>+</sup>), Th1  
204 (CD4<sup>+</sup>CD25<sup>lo</sup>CD127<sup>hi</sup>CD45RA<sup>-</sup>CXCR5<sup>-</sup>CXCR3<sup>+</sup>CCR6<sup>-</sup>), Th2 (CD4<sup>+</sup>CD25<sup>lo</sup>CD127<sup>hi</sup>CD45RA<sup>-</sup>



205 CXCR5<sup>-</sup>CXCR3<sup>-</sup>CCR6<sup>-</sup>) and Th17 (CD4<sup>+</sup>CD25<sup>lo</sup>CD127<sup>hi</sup>CD45RA<sup>-</sup>CXCR5<sup>-</sup>CXCR3<sup>-</sup>CCR6<sup>+</sup>)  
206 subsets determined<sup>20</sup>.

207

### 208 **Analysis of cytokine expression/secretion by CD4<sup>+</sup> and CD8<sup>+</sup> T cells**

209 Naive and memory CD4<sup>+</sup> T cells or naïve, memory and T<sub>EMRA</sub> CD8<sup>+</sup> T cells<sup>22</sup> were isolated by  
210 sorting on a FACS ARIA (Becton Dickinson; > 98% purity) and cultured with TAE beads (anti-  
211 CD2/CD3/CD28) in 96 well round bottomed well plates. After 5 days, supernatants were  
212 harvested and production of IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A, IL-17F, IFN $\gamma$  and  
213 TNF $\alpha$  determined by cytometric bead arrays (CBA; Becton Dickinson). For cytokine  
214 expression, activated T cells were re-stimulated with PMA (100 ng/ml) and ionomycin (750  
215 ng/ml) for 6 hours, with Brefeldin A (10  $\mu$ g/ml) added after 2 hours. Cells were then fixed with  
216 formaldehyde and expression of IFN $\gamma$ , IL-4, IL-17A, IL-22, IL-21, IL-10, TNF $\alpha$  and IL-2  
217 detected by intracellular staining<sup>20, 26-28</sup>.

218

### 219 **Analysis of transcription factor expression by CD4<sup>+</sup> T cells**

220 Expression of Tbet and GATA3 protein was assessed by intracellular staining using a Fix/Perm  
221 kit from eBioscience. Expression of *RORC* was determined by QPCR<sup>28</sup>.

222

### 223 **Analysis of DOCK8 expression**

224 To determine intracellular DOCK8 expression, PBMCs were fixed with formaldehyde and  
225 stained with an unconjugated DOCK8 or an isotype control IgG1 mAb. PE-rat anti-mouse IgG1  
226 was then used with saponin as the permeablising agent<sup>29</sup>.

227

### 228 **Analysis of CD4<sup>+</sup> T cell proliferation**

229 Naïve and memory CD4<sup>+</sup> T cells were isolated by sorting and then labeled with CFSE. Their  
230 proliferation status was determined by assessing dilution of CFSE after 5 days of *in vitro*  
231 culture<sup>27, 28</sup>.

232

### 233 ***In vitro* Th1, Th2, Th17 cell differentiation**

234 Naive and memory CD4<sup>+</sup> T cells were isolated by sorting and cultured under Th0 (TAE beads  
235 alone), or Th1 (50 ng/ml IL-12), Th2 (100 U/ml, IL-4) or Th17 (2.5 ng/mL TGF $\beta$ , 50 ng/mL  
236 IL-1 $\beta$ , 50 ng/mL IL-6, 50 ng/mL IL-21, 50 ng/mL IL-23, 50 ng/mL PGE2) polarising  
237 conditions. After 5 days cytokine secretion was analysed (CBA, intracellular staining)<sup>26, 28, 30</sup>.

238

### 239 **ImmunoCAP assay**

240 Plasma from normal donors and DOCK8-deficient patients was analysed for allergen specific

241 IgE Abs by the Sydney South West Pathology Service (Royal Prince Alfred Hospital, Sydney  
242 Australia) using the Phadia 250 ImmunoCAP platform (Thermo Scientific). IgE specific for a  
243 staple food mix (FX5; egg white, milk, codfish, wheat, peanut and soyabean) or house dust mite  
244 mix was determined.

## 245 246 **Statistical analysis**

247 Significant differences were determined using either a Students *t*-test, multiple t-tests, one-way  
248 or two-way ANOVA (Prism; GraphPad Software).

249

## 250 **RESULTS**

### 251 *Effects of DOCK8 deficiency on the generation of effector CD4<sup>+</sup> T cell subsets in vivo.*

252 As an initial step in investigating CD4<sup>+</sup> T cell function in the absence of DOCK8, we assessed  
253 the CD4<sup>+</sup> T cell compartment to determine whether the generation and differentiation of CD4<sup>+</sup>  
254 T cells was affected by DOCK8 deficiency and whether this could contribute to the combined  
255 immunodeficiency typical of these individuals. We previously investigated the peripheral T cell  
256 compartment in a small cohort (n = 6) of DOCK8-deficient patients<sup>22</sup>. We have now increased  
257 our cohort to comprise 18 individuals from 15 unrelated families and have extended our  
258 analysis to include additional surface markers to further distinguish different subsets within the  
259 CD4<sup>+</sup> T cell population (**Fig 1**). Lack of DOCK8 expression in lymphocytes and monocytes  
260 from a representative healthy control, one unaffected sibling and 4 DOCK8-deficient patients is  
261 depicted in Supplementary Fig 1. Analysis of this larger cohort of DOCK8-deficient patients  
262 confirmed a statistically significant reduction in CD4<sup>+</sup> T cells compared to normal donors (**Fig**  
263 **1A**). Naïve, central memory (T<sub>CM</sub>) and effector memory (T<sub>EM</sub>) CD4<sup>+</sup> T cells can be resolved  
264 according to the differential expression of CD45RA and CCR7<sup>31</sup> (**Fig 1B**). This analysis  
265 revealed that the naïve and T<sub>CM</sub> compartments in DOCK8-deficient patients are comparable to  
266 normal individuals, but T<sub>EM</sub> CD4<sup>+</sup> T cells were significantly increased in DOCK8-deficient  
267 patients (**Fig 1C**). Hence, despite the reduction in total CD4<sup>+</sup> T cells, DOCK8-deficient CD4<sup>+</sup> T  
268 cells differentiate normally into naïve and T<sub>CM</sub> cells; this is accompanied by a mild increase in  
269 T<sub>EM</sub> cells.

270

271 Using a recently described gating strategy<sup>20, 32</sup>, we next examined the CD4<sup>+</sup> T cell compartment  
272 for additional effector subsets: CD25<sup>hi</sup>CD127<sup>lo</sup> Tregs (**Fig 1D, G**)<sup>33</sup>, CXCR5<sup>+</sup>CD45RA<sup>-</sup> T  
273 follicular helper (T<sub>fh</sub>) cells (**Fig 1E, G**), CD45RA<sup>-</sup>CXCR5<sup>-</sup> CXCR3<sup>+</sup>CCR6<sup>-</sup> Th1 (**Fig 1F, G**),  
274 CD45RA<sup>-</sup>CXCR5<sup>-</sup> CXCR3<sup>-</sup>CCR6<sup>-</sup> Th2 (**Fig 1F, G**), and CD45RA<sup>-</sup>CXCR5<sup>-</sup> CXCR3<sup>-</sup>CCR6<sup>+</sup>

275 Th17 (**Fig 1F, G**) cells. DOCK8-deficient patients had an increased frequency of Tregs (**Fig**  
276 **1D, G**) but decreased frequency of Th17 cells (**Fig 1F, G**), while frequencies of Tfh, Th1 and  
277 Th2 cells according to this phenotypic delineation in patients were similar to normal donors  
278 (**Fig 1D - G**). Thus, there is a selective paucity of Th17 cells due to DOCK8 mutations.

279  
280 Assessment of expression of additional surface markers associated with CD4<sup>+</sup> T cell  
281 differentiation indicated that the naïve, T<sub>CM</sub> and T<sub>EM</sub> CD4<sup>+</sup> T cell populations from DOCK8-  
282 deficient patients had undergone greater activation and terminal differentiation than  
283 corresponding CD4<sup>+</sup> T cell subsets isolated from normal donors (**Fig 1H-M**). Specifically, the  
284 loss of expression of CD27 (**Fig 1H**), CD28 (**Fig 1I**) and CD127 (**Fig 1J**) and acquisition of  
285 CD57 (**Fig 1K**), CD95 (**Fig 1L**) and PD-1 (**Fig 1M**) by CD4<sup>+</sup> T<sub>CM</sub> and T<sub>EM</sub> cells was  
286 exaggerated for DOCK8-deficient patients compared to controls. Collectively, DOCK8  
287 deficiency compromises the generation of Th17 cells, and results in the premature terminal  
288 differentiation of memory cells such that they acquire a senescent/exhausted phenotype.

289

#### 290 *DOCK8 deficient memory CD4<sup>+</sup> T cells are biased towards Th2 cytokines.*

291 Given the decrease in CCR6<sup>+</sup>CXCR3<sup>-</sup> cells – which are enriched for Th17-cytokine producing  
292 cells in healthy donors<sup>20, 34-36</sup> – in DOCK8-deficient patients, we investigated cytokine  
293 expression by naïve and memory CD4<sup>+</sup> T cells (**Fig 2**). Naïve and total memory (CD45RA<sup>-</sup>  
294 CCR7<sup>+/-</sup>) CD4<sup>+</sup> T cells were sort-purified from normal donors and DOCK8-deficient patients  
295 and then cultured with TAE beads conjugated to anti-CD2/CD3/CD28 mAbs for 5 days. After  
296 this time cells were restimulated with PMA/ionomycin and intracellular expression of IFN $\gamma$ , IL-  
297 4, IL-17A, IL-22, IL-21, IL-10, TNF $\alpha$  and IL-2 determined (**Fig 2**). Apart from IL-2 (**Fig 2A**)  
298 and TNF $\alpha$  (**Fig 2B**), which are expressed by 40-80% of normal naïve cells, only a small  
299 proportion of naïve cells (ie <5%) expressed any of the other cytokines examined. DOCK8-  
300 deficient naïve CD4<sup>+</sup> T cells expressed a comparable level of IL-2 (**Fig 2A**) and TNF $\alpha$  (**Fig 2B**)  
301 to that of normal naïve CD4<sup>+</sup> T cells. However, analysis of the memory CD4<sup>+</sup> T cell  
302 compartment in DOCK8-deficient patients revealed marked perturbations in differentiation *in*  
303 *vivo*. A significantly greater proportion of DOCK8-deficient memory CD4<sup>+</sup> T cells expressed  
304 IL-4 compared to normal memory CD4<sup>+</sup> T cells (**Fig 2C**), suggesting a skewing to the Th2  
305 effector lineage. Examination of mean fluorescence intensity of IL-4<sup>+</sup> cells in DOCK8-deficient  
306 and normal memory CD4<sup>+</sup> T cells revealed no significant differences (data not shown),  
307 suggesting there is an increase in the frequency of IL-4 expressing cells in the DOCK8 memory

308 CD4<sup>+</sup> T cell compartment, but a comparable amount of IL-4 is produced per cell. The increase  
309 in IL-4<sup>+</sup> cells in DOCK8-deficient memory CD4<sup>+</sup> T cells was accompanied by significant  
310 reductions in expression of Th1 cytokines IFN $\gamma$  (**Fig 2D**) and TNF $\alpha$  (**Fig 2B**), Th17 cytokines  
311 IL-17A (**Fig 2E**) and IL-22 (**Fig 2F**), and the Tfh cytokine IL-21 (**Fig 2G**). Expression of IL-10  
312 (**Fig 2H**) and IL-2 (**Fig 2A**) by memory CD4<sup>+</sup> T cells was unaffected by DOCK8 deficiency.

313  
314 The Th2 skewing by DOCK8-deficient memory CD4<sup>+</sup> T cells was also assessed by measuring  
315 cytokine secretion during the 5-day culture (**Fig 3**). This indicated concordance between  
316 expression and secretion of cytokines when assessed by intracellular staining and flow  
317 cytometry or cytometric bead array, respectively. Analysis of an extended panel of cytokines  
318 showed that DOCK8-deficient memory T cells secreted not only more IL-4 than normal  
319 memory CD4<sup>+</sup> T cells, but also more of the Th2 cytokines IL-5 and IL-13 (**Fig 3A-C**) and less  
320 Th1 (IFN $\gamma$  and TNF $\alpha$ ; **Fig 3D, E**) and Th17 (IL-17A and IL-17F; **Fig 3F, G**) cytokines.  
321 Production of IL-6 (**Fig 3H**) was also significantly reduced. There were trends for less  
322 production of IL-10 and IL-2 by DOCK8-deficient memory CD4<sup>+</sup> T cells, however these  
323 reduced values were not significant (**Fig 3I, J**). Production of TNF $\alpha$  and IL-2 by DOCK8-  
324 deficient naïve CD4<sup>+</sup> T cells was normal (**Fig 3E, J**). Taken together, memory CD4<sup>+</sup> T cells  
325 from DOCK8-deficient patients display a Th2 bias, primarily expressing IL-4, IL-5 and IL-13  
326 and notably lower levels of cytokines characteristic of other T helper subsets.

327  
328 ***Th2 cytokine bias by DOCK8-deficient memory CD4<sup>+</sup> T cells is independent of defects in cell***  
329 ***proliferation.***

330 Previous work showed that lymphocyte differentiation eg Ig class switching and antibody  
331 secretion by naïve B cells, and cytokine production and cell surface phenotype expression by  
332 naïve T cells, is regulated by cell division<sup>27, 37-39</sup>. DOCK8-deficient naïve (Fig 3K) and memory  
333 (Fig 3L) CD4<sup>+</sup> T cells were found to have impaired cell division *in vitro*, consistent with  
334 previous findings<sup>22</sup>. Thus, it was possible that the perturbed cytokine profile reflected reduced  
335 proliferation by DOCK8-deficient memory CD4<sup>+</sup> T cells. However, the Th2 bias of DOCK8-  
336 deficient memory CD4<sup>+</sup> T cells was not due to a proliferative defect as evidenced by two  
337 important and related findings. First, when memory cells were isolated and restimulated  
338 immediately for analysis of cytokine expression, the preferential production of IL-4 by  
339 DOCK8-deficient over normal memory CD4<sup>+</sup> T cells was still observed in the absence of cell  
340 proliferation (**Fig 3M**). Similarly, the poor production of Th1 and Th17 cytokines by DOCK8-

341 deficient memory CD4<sup>+</sup> T cells did not result from impaired proliferation because reductions in  
342 expression of IFN $\gamma$  (normal: 17.7%, DOCK8: 6.9%) and IL-22 (normal: 3.7%, DOCK8: 1.8%)  
343 respectively were also observed when assessed under these *ex vivo* stimulatory conditions.  
344 Second, analysis of cells that had undergone different rounds of divisions *in vitro* revealed that  
345 the decrease in IFN $\gamma$  (**Fig 3N**) and increase in IL-4 (**Fig 3O**) displayed by DOCK8-deficient  
346 versus normal memory CD4<sup>+</sup> T cells was evident for all division intervals examined. Thus, the  
347 preference of DOCK8-deficient memory CD4<sup>+</sup> T cells to produce Th2, but not Th1, cytokines  
348 is independent of any proliferative defects in these cells.

349  
350 ***Naïve DOCK8-deficient CD4<sup>+</sup> T cells can differentiate into effector cells producing Th1 and***  
351 ***Th2, but not Th17, cytokines in vitro.***

352 To determine if the defects in cytokine production by DOCK8-deficient memory CD4<sup>+</sup> T cells  
353 are cell-intrinsic or due to extrinsic factors, we isolated naïve CD4<sup>+</sup> T cells from normal donors  
354 and DOCK8-deficient patients and subjected them to *in vitro* culture under Th0, Th1, Th2 or  
355 Th17 polarising conditions. Interestingly, DOCK8-deficient naïve CD4<sup>+</sup> T cells differentiated  
356 into Th1 cells (IFN $\gamma$  and TNF $\alpha$ ) to the same extent as normal naïve CD4<sup>+</sup> T cells (**Fig 4A, left**  
357 **panel**). Consistent with the data for memory CD4<sup>+</sup> T cells *ex vivo*, DOCK8-deficient naïve  
358 CD4<sup>+</sup> T cells produced significantly greater amounts of the Th2 cytokine IL-13 than control  
359 naïve CD4<sup>+</sup> T cells under Th2-polarising conditions (3-fold increase; **Fig 4A, middle panels**).  
360 We also analysed Th2 differentiation by assessing cytokine expression in naïve CD4<sup>+</sup> T cells by  
361 intracellular staining and flow cytometry following *in vitro* Th2 polarization. This confirmed a  
362 preferential differentiation of DOCK8-deficient towards a Th2 fate, with increased proportions  
363 of DOCK8-deficient naïve CD4<sup>+</sup> T cells expressing IL-4 (9.9% DOCK8-deficient vs 5.5%  
364 control CD4<sup>+</sup> T cells) and IL-13 (5.9% DOCK8-deficient vs 1.7% control CD4<sup>+</sup> T cells).  
365 Together, these data provide evidence of a predominant intrinsic bias of DOCK8-deficient  
366 naïve CD4<sup>+</sup> T cells differentiating towards a Th2 effector fate. DOCK8-deficient naïve CD4<sup>+</sup> T  
367 cells failed to differentiate into IL-17A- and IL-17F-secreting cells when subjected to Th17  
368 polarising conditions *in vitro* (**Fig 4A, right panels**). Notably, DOCK8-deficient naïve CD4<sup>+</sup> T  
369 cells responded to the Th17 culture as shown by reductions in basal levels of IL-5 and IL-13  
370 secretion compared to the Th0 culture (data not shown).

371  
372 When we examined memory CD4<sup>+</sup> T cells from healthy donors, production of IFN $\gamma$  and IL-  
373 17A/F could be increased ~2-4 fold by Th1 and Th17 culture conditions, respectively,

374 compared to Th0 conditions (**Fig 4B**). The net increase in production of these cytokines by  
375 DOCK8-deficient memory CD4<sup>+</sup> T cells under Th1 and Th17 conditions compared to Th0  
376 conditions was also ~2-6 fold. Despite this, the levels of IFN $\gamma$  and IL-17A/F secreted by Th1-  
377 and Th17-stimulated DOCK8-deficient memory CD4<sup>+</sup> T cells were substantially less than not  
378 only Th1- and Th17-stimulated normal memory CD4<sup>+</sup> T cells, but also Th0-stimulated normal  
379 memory CD4<sup>+</sup> T cells (**Fig 4B**). This likely reflects expansion of the few Th1 and Th17 cells  
380 present in the DOCK8 memory CD4<sup>+</sup> T cell compartment rather than *de novo* differentiation  
381 into these effector subsets *in vitro*.

382  
383 Consistent with the data for cytokine secretion, DOCK8-deficient naïve CD4<sup>+</sup> T cells that were  
384 polarised towards Th1 and Th2 fates upregulated TBET (**Fig 4C**) and GATA3 (**Fig 4D**),  
385 respectively, to the same extent as normal naïve CD4<sup>+</sup> T cells. In our hands, detection of ROR $\gamma$ t  
386 expression by flow cytometry was not particularly sensitive, as we found that only a small  
387 proportion of naïve CD4<sup>+</sup> T cells (~5%) expressed ROR $\gamma$ t in Th17 compared to Th0 activated  
388 cultures<sup>40</sup>. To overcome this, *RORC* expression was determined by QPCR. *RORC* was not  
389 expressed by naïve CD4<sup>+</sup> T cells activated under Th0 conditions, but was up-regulated in  
390 normal and DOCK8-deficient naïve CD4<sup>+</sup> T cells cultured under Th17 polarising conditions  
391 (**Fig 4E**). Taken together, these data indicate the Th17 cytokine defect in DOCK8 deficiency is  
392 T cell intrinsic, and cannot be restored by Th17 polarising conditions for either naïve or  
393 memory cells. Furthermore, the ability of Th17 culture conditions to induce *RORC* in the  
394 absence of DOCK8 indicates the defect in Th17 differentiation is downstream of *RORC*. In  
395 contrast, DOCK8-deficient naïve CD4<sup>+</sup> T cells differentiate normally into Th1 cells, and exhibit  
396 exaggerated Th2 differentiation, when provided with the appropriate stimuli *in vitro*.

397  
398 ***Preferential production of Th2 cytokines by DOCK8-deficient CD4<sup>+</sup> T cells correlates with***  
399 ***reduced TCR-mediated activation***

400 The strength of signal provided to CD4<sup>+</sup> T cells through the TCR greatly influences their  
401 differentiation to cytokine-producing effector cells. For instance, reduced signal strength  
402 favours Th2 cells<sup>41-44</sup>, while differentiation to Th17 cells requires stronger or sustained TCR  
403 signalling<sup>45, 46</sup>. Our findings of heightened production of Th2 cytokines by DOCK8-deficient  
404 naïve and memory CD4<sup>+</sup> T cells led us to hypothesise that mutations in DOCK8 compromised  
405 TCR signal strength. To assess this, we cultured DOCK8-deficient CD4<sup>+</sup> T cells with differing  
406 doses of anti-CD2/CD3/CD28 beads for 3 days and then measured levels of expression of the

407 activation molecules ICOS, CD25, CD69, and CD95. The rationale here is that lowering the  
408 dose of the beads results in a qualitatively weaker signal. While CD4<sup>+</sup> T cells from healthy  
409 controls exhibited heightened expression of ICOS, CD69, CD25 at the 2 different doses of anti-  
410 CD2/CD3/CD28 beads tested, induction of these same molecules on DOCK8-deficient CD4<sup>+</sup> T  
411 cells was severely blunted (**Fig 4F**). Thus, mutations in *DOCK8* compromise T cell activation  
412 by reducing the strength of signal delivered through the TCR and co-stimulatory receptor  
413 signaling pathways. In the case of T cell differentiation, this results in a skewing of the cells  
414 towards a Th2 phenotype.

415  
416 ***Specific sensitisation of DOCK8-deficient patients to food allergens***  
417 Exaggerated Th2 immune responses have traditionally been associated with allergy and atopic  
418 disease<sup>47</sup>. It was thus intriguing to note that CD4<sup>+</sup> T cells from DOCK8-deficient patients were  
419 biased towards production of Th2 cytokines, and that these patients have severe allergies. To  
420 determine if the Th2 bias in DOCK8-deficient human CD4<sup>+</sup> T cells is related to their increased  
421 susceptibility to food allergies we examined the specificity of IgE in serum samples from  
422 DOCK8-deficient patients and normal healthy donors to staple foods (i.e. egg white, milk,  
423 codfish, wheat, peanut, soyabean), as well as to non-food allergens such as house dust mites.  
424 We found that a comparable frequency of normal individuals and DOCK8-deficient patients  
425 had IgE specific to house dust mites (**Fig 5A**). Strikingly, the majority of plasma samples from  
426 DOCK8-deficient patients (80%; 12/15), but none of the normal controls tested, had IgE that  
427 was specific for the staple food mix (**Fig 5B**). Thus, DOCK8-deficient patients have a Th2 bias  
428 that manifest clinically as specific sensitisation to oral allergens and this may explain the  
429 marked propensity of these immunodeficient patients to develop food allergies.

430  
431 **DISCUSSION**  
432 Identifying defects in lymphocyte development or function in PIDs provides the opportunity to  
433 elucidate the cellular and molecular basis for the clinical features of the disease. Studies of  
434 DOCK8-deficient humans and mice have indeed revealed critical cell-intrinsic roles for  
435 DOCK8 in generating B-cell memory and long-lived humoral immunity<sup>5, 48</sup>, CD8<sup>+</sup> T cell  
436 differentiation and anti-viral responses<sup>22, 23, 49, 50</sup>, NK cell cytotoxicity<sup>24</sup> and NKT cell  
437 development<sup>25</sup>. Collectively, these defects underlie poor Ab responses to specific Ags, and  
438 impaired cell-mediated immunity to pathogens including HSV, HPV and *Molluscum*  
439 *contagiosum* virus. We have now investigated CD4<sup>+</sup> T cell differentiation in DOCK8-deficient

440 patients to understand other aspects of AR-HIES, such as susceptibility to bacterial and fungal  
441 infections, atopic disease, food allergies and hyper-IgE.

442  
443 Our data revealed that DOCK8-deficient CD4<sup>+</sup> T cells have dysregulated expression of surface  
444 molecules including CD27, CD57, CD95 and PD-1. This likely results from chronic infection  
445 with pathogens, such as herpes viruses (HSV, CMV, VZV), HPV and *Molluscum contagiosum*  
446 virus, akin to what has been described for CD8<sup>+</sup> T cells in not only DOCK8 deficiency<sup>22</sup>, but  
447 other PIDs such as XLP<sup>51, 52</sup>, STAT3 deficiency<sup>53</sup> and *PIK3CD* gain of function mutations<sup>54</sup>,  
448 which are characterised by chronic exposure to infectious pathogens. In the absence of DOCK8,  
449 memory CD4<sup>+</sup> T cells are polarised to a Th2 cytokine phenotype at the expense of Th1 and  
450 Th17 cytokines. The reduction in Th17 cells was apparent not only from the lack of cells  
451 producing IL-17A, IL-17F and IL-22, but also the reduction in CCR6<sup>+</sup> memory CD4<sup>+</sup> T cells.  
452 This is consistent with our previous studies which revealed parallel reductions in CD4<sup>+</sup> T cells  
453 secreting IL-17A/IL-17F and expressing CCR6<sup>+</sup> in patients with *STAT3* loss-of function or  
454 *STAT1* gain-of function mutations<sup>17, 20, 28</sup>, indicating that flow cytometric analysis of CCR6<sup>+</sup>  
455 memory CD4<sup>+</sup> T cells can be a reliable and rapid means of quantifying Th17 cells.  
456 Interestingly, DOCK8-deficient naïve CD4<sup>+</sup> T cells differentiated into TBET-expressing and  
457 Th1-cytokine secreting cells when provided with exogenous signals *in vitro*. This suggests that  
458 defects in IFN $\gamma$  production by DOCK8-deficient memory CD4<sup>+</sup> T cells *ex vivo* are extrinsic,  
459 possibly resulting from suboptimal priming by Ag-presenting cells and provision of IL-12 *in*  
460 *vivo*. Consistent with this, DOCK8-deficient murine DCs failed to accumulate in the lymph  
461 node parenchyma where they are required for T cell priming during immune responses<sup>55</sup>. This  
462 defect was attributed to compromised Cdc42 function in the absence of DOCK8<sup>55</sup>. Another  
463 possibility is that excessive production of IL-4, which restrains differentiation of human CD4<sup>+</sup>  
464 T cells into Th1 cells<sup>56</sup>, impairs IFN $\gamma$  production by DOCK8-deficient memory CD4<sup>+</sup> T cells.  
465 This is consistent with our recent observations of heightened production of Th2 cytokines and  
466 corresponding reductions in IFN $\gamma$  production *ex vivo* by memory CD4<sup>+</sup> T cells from individuals  
467 with loss-of function mutations in *STAT3*, *IL21R*, *IL12RB1*, *TYK2* or *RORC*<sup>20, 57</sup>. While  
468 DOCK8-deficient naïve CD4<sup>+</sup> T cells could express *RORC* *in vitro* following activation under  
469 Th17-polarising conditions, IL-17A/F cytokine secretion remained greatly impaired. Thus, an  
470 intrinsic defect distal to inducing *RORC* expression underlies the inability of DOCK8-deficient  
471 CD4<sup>+</sup> T cells to become Th17 cells. Although Th1- and Th17-polarising conditions did increase  
472 IFN $\gamma$  and IL-17A/F production by DOCK8-deficient memory CD4<sup>+</sup> T cells, these cells



473 produced lower levels of these cytokines than normal cells under similar culture conditions.  
474 Interestingly, CD4<sup>+</sup> T cells from DOCK8-deficient mice expressed normal levels of TBET and  
475 GATA3 when activated under Th1 and Th2 polarising conditions, respectively, *in vitro*<sup>49</sup>.  
476 Interestingly, while IFN $\gamma$  expression by *in vitro*-derived murine DOCK8-deficient Th1 cells  
477 was normal, Th2 polarised DOCK8-deficient CD4<sup>+</sup> T cells showed increases in IL-4-expressing  
478 cells<sup>49</sup>, suggesting that murine DOCK8 deficient CD4<sup>+</sup> T cells also display a Th2 bias.

479  
480 These findings provide potential explanations for some of the clinical features of DOCK8  
481 deficiency. First, lack of Th17 cells would predispose DOCK8-deficient individuals to  
482 infections with *Candida albicans*. This is akin to other monogenic PIDs characterised by  
483 impaired Th17/IL-17-mediated immunity and the high incidence of chronic mucocutaneous  
484 candidiasis (CMC) in affected individuals ie loss-of-function mutations in *STAT3*, *IL17RA*,  
485 *IL17RC*, *IL17F*, *ACT1* and *RORC*, and gain-of-function mutations in *STAT1*<sup>20, 28, 57-62</sup>.  
486 Compared to other PIDs with defects in Th17 cytokines, IL-17A/IL-17F production by  
487 DOCK8-deficient memory CD4<sup>+</sup> T was less than that observed for *RORC*- or *STAT3*-deficient  
488 memory CD4<sup>+</sup> T cells<sup>20, 57</sup>. Remarkably, the quantitative impact of specific gene mutations on  
489 generating Th17 cells correlates with, or predicts, the incidence of fungal infections in these  
490 individuals. Thus, ~85% of patients with mutations in *STAT3* or *RORC* develop CMC<sup>57, 63</sup>, but  
491 fungal infections is observed in only ~40-60% of DOCK8-deficient patients, as shown for the  
492 cohort studied here (Table 1), and in a larger study of 57 patients<sup>64</sup>. Thus, there is likely a direct  
493 association between IL-17A/IL-17F production in different PID patients and incidence of  
494 CMC. Second, the predominance of memory CD4<sup>+</sup> T cells producing high levels of IL-4, IL-5  
495 and IL-13 could contribute to the characteristic pathophysiological Th2 features of AR-HIES:  
496 severe allergy, eosinophilia and hyper-IgE<sup>65</sup>. This exaggerated Th2 response may also reduce  
497 Th17 differentiation<sup>66</sup>, further compromising Th17-mediated anti-fungal immune responses.  
498 Although memory CD4<sup>+</sup> T cells displayed reduced IFN $\gamma$  production *ex vivo*, DOCK8-deficient  
499 naïve CD4<sup>+</sup> T cells could differentiate into Th1 cells *in vitro*. Thus, Th1-mediated immunity,  
500 while reduced, may be sufficient in these individuals to elicit protective immunity. Indeed, this  
501 is consistent with a lack of disease caused by poorly virulent mycobacteria, such as BCG  
502 vaccines and environmental species - which require IFN $\gamma$ -mediated immunity for protection<sup>67</sup> -  
503 in DOCK8 deficiency. In the scenario of anti-viral immunity, the increased Th2-cytokine  
504 environment within the memory CD4<sup>+</sup> T cell compartment may inhibit IFN $\gamma$  production by  
505 CD8<sup>+</sup> T cells. Indeed, analysis of DOCK8-deficient memory CD8<sup>+</sup> T cells *ex vivo* revealed

506 defective IFN $\gamma$  expression and secretion compared to healthy donors (Supplementary Fig 2A,  
507 B)<sup>1</sup>. Thus, by diminishing Th1 responses, a Th2 bias could contribute to persistent viral  
508 infections in DOCK8-deficient patients. Third, beyond Th1, Th2 and Th17 cytokines, we also  
509 noted reduced production of IL-6 by DOCK8-deficient memory CD4<sup>+</sup> T cells. While there have  
510 been no genetic studies linking impaired IL-6 production with infection with specific  
511 pathogens, autoantibodies against IL-6 were reported in an individual with recurrent  
512 staphylococcal infection<sup>68</sup>. Thus it is possible that poor IL-6-mediated immunity in DOCK8  
513 deficiency underlies staphylococcal infection in affected patients. Fourth, while previous work  
514 demonstrated that DOCK8 functions intrinsically in B cells to regulate differentiation, reduced  
515 production of IL-21 (and potentially IL-10) by DOCK8-deficient memory CD4<sup>+</sup> T cells may  
516 also contribute to impaired humoral immune responses in AR-HIES, as these cytokines are the  
517 main drivers of human B cell activation, proliferation and differentiation<sup>69</sup>. This is supported by  
518 our observation that DOCK8-deficient memory CD4<sup>+</sup> T cells present with defects in IL-21  
519 expression *ex vivo* (Figure 2) and naïve DOCK8-deficient CD4<sup>+</sup> T cells failed to differentiate  
520 into IL-21+ cells as efficiently as normal naïve CD4<sup>+</sup> T cells when cultured under Tfh cell  
521 polarising conditions (Supplementary Fig 2C).

522  
523 A characteristic and perhaps unique feature of DOCK8 deficiency compared to other PIDs  
524 (including those in which there are high levels of IgE such as mutations in *STAT3*) is the very  
525 high incidence of food allergies<sup>1-5</sup>. The allergen-specific IgE from DOCK8-deficient patients  
526 was directed mostly towards staple foods rather than non-food allergens such as house dust  
527 mites. This is consistent with a recent report which showed that this pattern of allergen-specific  
528 IgE is unique to DOCK8 deficiency<sup>70</sup>, inasmuch that DOCK8 deficient patients had IgE  
529 directed towards food Ags, while patients with atopic dermatitis have IgE specific for  
530 aeroallergens, yet the reactivity of IgE in *STAT3*-deficient individuals against specific allergens  
531 was comparable to normal donors<sup>70</sup>. Since food allergies are more common in children who  
532 often outgrow them once they reach adolescence, IgE sensitisation to food Ags and not house  
533 dust mites in DOCK8 deficiency could be attributable to the younger age of our DOCK8 cohort  
534 compared to our normal controls. However, this is unlikely as 9 of the 12 DOCK8 deficient  
535 patients that still had IgE specific to food Ags were adolescents or adults. In the scenario of  
536 *STAT3* deficiency, the reduced level of IgE specific for food allergens when compared to  
537 patients with atopic dermatitis has been attributed to a defect in basophil activation and mast  
538 cell degranulation, with the latter process found to be *STAT3*-dependent<sup>71</sup>. This is interesting

539 because although patients with mutations in *DOCK8* or *STAT3*, or individuals with atopic  
540 dermatitis, all display increased serum IgE, eczema and atopic disease, *DOCK8* deficiency  
541 specifically predisposes to food allergies. The mechanism whereby this occurs is unclear, but it  
542 is tempting to speculate that it is related to the Th2 bias of *DOCK8*-deficient memory  $CD4^+$  T  
543 cells. While Th2 skewing has been reported in *DOCK8*-deficient mice *in vitro*<sup>49</sup>, to our  
544 knowledge, IgE responses following exposure to food allergens have not been investigated in  
545 mice, but may provide invaluable insights into whether exposure to food allergens is the driver  
546 of IgE production in *DOCK8* deficiency. Nevertheless, our findings reinforce the value of  
547 direct interrogation of patient cells and highlight the need to be cognisant of species-specific  
548 differences that impact translation of murine studies to humans.

549  
550 The underlying cause for the biased Th2 nature of memory  $CD4^+$  T cells in *DOCK8*-deficient  
551 patients remains to be determined. Examination of the TCR  $V\beta$  repertoire in the  $CD4^+$  T cell  
552 compartment of *DOCK8* deficient patients and healthy normal donors did not reveal any  
553 substantial differences (data not shown). However, there is evidence showing that the strength  
554 of the signal received through the TCR greatly influences differentiation of  $CD4^+$  T cells.  
555 Specifically, low doses of Ag/low level TCR signalling favour humoral or IL-4-mediated Th2  
556 immune responses while high doses of Ag/strong TCR signalling favour cellular or  $IFN\gamma$ -  
557 mediated Th1 immune responses<sup>41-43</sup>. This is also supported genetically, as murine  $CD4^+$  T  
558 cells with a hypomorphic *Card11* mutation reduces TCR-mediated signal strength resulting in  
559 exaggerated Th2 differentiation, allergic disease, dermatitis and hyper-IgE<sup>44</sup>. Based on this, we  
560 hypothesise that *DOCK8*-deficient  $CD4^+$  T cells receive a qualitatively weaker TCR signal,  
561 potential due to defective immunological synapse formation<sup>48</sup>, which favors their preferential  
562 differentiation into Th2 cells at the expense of other Th cell subsets. Our data demonstrating  
563 reduced induction of expression of activation markers on *DOCK8*-deficient  $CD4^+$  T cells in  
564 response to increasing doses of anti-CD2/CD3/CD28 bead stimulation supports this hypothesis.  
565 The original studies on strength of TCR signals influencing murine Th cell differentiation  
566 predated the discovery of Th17 cells. However, studies in mice and humans have since  
567 demonstrated a requirement for sustained TCR signalling in naïve T cells for commitment to a  
568 Th17 phenotype *in vitro* and *in vivo*<sup>45, 46</sup>. Thus, we would predict that reduced TCR signal  
569 strength in *DOCK8*-deficient  $CD4^+$  T cells impairs their differentiation into Th17 cells.

570

571 In conclusion we reveal that the CD4<sup>+</sup> T cell compartment is greatly altered in the absence of  
572 DOCK8. Specifically, DOCK8-deficient patients have increased Th2 cells and defects in Th1  
573 and Th17 cell differentiation. This skewing of CD4<sup>+</sup> T cell subsets likely accounts for some of  
574 the clinical manifestations in DOCK8-deficient individuals. Strikingly, within our DOCK8  
575 cohort, all the patients investigated had IgE that was specific for at least one of the following  
576 foods - egg white, milk, codfish, wheat, peanut and soyabean-, but not non-food allergens.  
577 These results indicate that the detection of high titers of IgE specific for food but not to other  
578 allergens is predictive of DOCK8 deficiency. Thus, future studies to identify signalling  
579 pathways and cellular processes affected by DOCK8 deficiency in CD4<sup>+</sup> T cells will not only  
580 improve our understanding of disease pathogenesis in affected DOCK8-deficient individuals,  
581 but also patients with atopic disease.

582

583 **Acknowledgements**

584 We would like to thank Rob Salomon, Eric Lam, and Vitri Dewi from the Garvan Institute  
585 Flow facility for cell sorting, Helen Matthews (NIAID, NIH) for clinical support, Kathryn Payne  
586 (Garvan Institute) for technical support, and all of the patients and their families for  
587 participating in this project. This work was supported by research grants awarded by the  
588 National Health and Medical Research Council (NHMRC) of Australia (to CSM and SGT,  
589 1060303, 596813, 1016953; to KLR, 1022922), and Rockefeller University Center for  
590 Clinical and Translational Science (5UL1RR024143, to JLC). This research was supported in  
591 part by the Intramural Research Program of the NIH, NIAID. CSM is a recipient of a Career  
592 Development Fellowship (1008820) and SGT a Principal Research Fellowship (1042925) from  
593 the NHMRC of Australia, and a Fulbright Senior Scholar.

594

595

596 **FIGURES LEGENDS**

597 **Figure 1: Phenotype of the peripheral CD4<sup>+</sup> T cell compartment in DOCK8-deficient**  
 598 **patients.** (A) The frequency of CD4<sup>+</sup> T cells in normal donors and DOCK8-deficient patients.  
 599 (B, C) Naïve (CD45RA<sup>+</sup>CCR7<sup>+</sup>), central memory (T<sub>CM</sub>; CD45RA<sup>-</sup>CCR7<sup>+</sup>) and effector  
 600 memory (T<sub>EM</sub>; CD45RA<sup>-</sup>CCR7<sup>-</sup>) populations in normal donors (closed symbol; n = 25) and  
 601 DOCK8-deficient patients (open symbol; n = 18) were enumerated based on expression of  
 602 CD45RA and CCR7. (D-G) PBMCs were labelled with mAbs against CD4, CD45RA, CD25,  
 603 CD127, CXCR5, CXCR3 and CCR6. (D) Treg cells were identified as CD25<sup>hi</sup>CD127<sup>lo</sup>. (E)  
 604 Amongst the non-Treg population naïve and Tfh cells were identified as CXCR5<sup>-</sup>CD45RA<sup>+</sup> and  
 605 CXCR5<sup>+</sup>CD45RA<sup>-</sup>, respectively. (F) Th1, Th2 and Th17 populations were identified within the  
 606 population of CXCR5<sup>-</sup>CD45RA<sup>-</sup> memory CD4<sup>+</sup> T cells as CXCR3<sup>+</sup>CCR6<sup>-</sup>, CCR6<sup>-</sup>CXCR3<sup>-</sup> and  
 607 CCR6<sup>+</sup>CXCR3<sup>-</sup> cells, respectively. (G) Using this gating the frequency of Tregs, Tfh, Th1, Th2  
 608 and Th17 cells within the CD4<sup>+</sup> T cell compartment was determined in normal individuals  
 609 (closed symbol; n = 15 or 16) and in DOCK8-deficient patients (open symbol; n = 10 or 11).  
 610 Each point represents an individual donor or patient. Statistics performed with Prism using  
 611 Student t-test. (H-M) Naïve (CD45RA<sup>+</sup>CCR7<sup>+</sup>), central memory (T<sub>CM</sub>; CD45RA<sup>-</sup>CCR7<sup>+</sup>) and  
 612 effector memory (T<sub>EM</sub>; CD45RA<sup>-</sup>CCR7<sup>-</sup>) populations in normal donors (closed symbol) and  
 613 DOCK8-deficient patients (open symbol) were identified and assessed for expression of (H)  
 614 CD27, (I) CD28, (J) CD127, (K) CD57, (L) CD95 and (M) PD1. Each point corresponds to the  
 615 mean ± SEM % of cells expressing the indicated surface receptor, or MFI (mean fluorescence  
 616 intensity) of expression (n = 4 - 12 normal donors or DOCK8-deficient individuals). Statistics  
 617 performed with Prism using t-test.

618  
 619 **Figure 2: DOCK8-deficient memory CD4<sup>+</sup> T cells display a Th2 cytokine expression bias.**  
 620 Naïve (CD45RA<sup>+</sup>CCR7<sup>+</sup>) and memory (CD45RA<sup>-</sup>CCR7<sup>+/-</sup>) CD4<sup>+</sup> T cells were isolated from  
 621 normal donors and DOCK8-deficient patients and cultured with TAE beads for 5 days. Cells  
 622 were then re-stimulated with PMA/ionomycin for 6 hours in the presence of Brefeldin A for the  
 623 last 4 hours. Intracellular expression of (A) □□□□, (B) TNFα, (C) IL-4, (D) IFNγ, (E) IL-  
 624 17A, (F) IL-22, (G) IL-21 and (H) IL-10 was determined using saponin as the permeabilising  
 625 agent followed by flow cytometric analysis. Data represent the mean ± SEM of 8 normal  
 626 donors or 8 DOCK8-deficient patients. Statistics performed with Prism using One-way  
 627 ANOVA.

628

629 **Figure 3: DOCK8-deficient memory CD4<sup>+</sup> T cells secrete elevated quantities of the Th2**  
 630 **cytokines IL-4, IL-5 and IL-13 independently of differences in cell proliferation.** Naïve and  
 631 memory CD4<sup>+</sup> T cells were sorted from normal donors and DOCK8-deficient patients and  
 632 cultured with TAE beads for 5 days. After this time, culture supernatants were examined for  
 633 secretion of (A) IL-4 (B) IL-5, (C) IL-13, (D) IFN $\gamma$ , (E) TNF, (F) IL-17A, (G) IL-17F, (H) IL-  
 634 6, (I) IL-10, (J) IL-2, using a custom designed cytometric bead array (CBA; BD biosciences).  
 635 Data represent the mean  $\pm$  SEM of experiments using cells from 9 normal donors or DOCK8-  
 636 deficient patients. Statistics performed with Prism using One-way ANOVA. (K-L) Naïve (K)  
 637 and memory (L) CD4<sup>+</sup> T cells were isolated from normal donors (n = 4) and DOCK8-deficient  
 638 patients (n = 4), labelled with CFSE and cultured with TAE beads for 5 days. After this time,  
 639 the frequency of cells in each division was determined by dilution of CFSE. (M) Sorted naïve  
 640 and memory CD4<sup>+</sup> were immediately restimulated with PMA/ionomycin for 6 hours in the  
 641 presence of Brefeldin A and IL-4 expression determined by intracellular staining and flow  
 642 cytometry. (N, O) Naïve and memory CD4<sup>+</sup> T cells were labelled with CFSE, cultured with  
 643 TAE beads for 5 days, and the proportion of cells expressing (L) IFN $\gamma$  or (M) IL-4 was  
 644 determined for each division interval by dilution of CFSE. Data represent the mean  $\pm$  SEM of 2  
 645 - 4 normal donors and DOCK8-deficient patients.

647 **Figure 4: Intrinsic defects in CD4<sup>+</sup> T cell cytokine secretion due to DOCK8 mutations.** (A)  
 648 Naïve and (B) memory CD4<sup>+</sup> T cells were isolated from normal donors and DOCK8-deficient  
 649 patients and activated under neutral conditions (Th0; TAE only), or Th1- (+ IL-12), Th2- (+ IL-  
 650 4), or Th17- (+ IL-1 $\beta$ , IL-6, IL-21, IL-23, TGF $\beta$ , PG) polarising conditions. After 5 days,  
 651 secretion of Th1 (IFN $\gamma$ ), Th2 (IL-5, IL-13) and Th17 (IL-17A, IL-17F) cytokines was  
 652 determined by CBA. The data represent the mean  $\pm$  SEM of experiments using cells from 12  
 653 normal donors and 8 DOCK8-deficient patients. Expression of (C) TBET and (D) GATA3 was  
 654 determined by flow cytometry; the data represent the fold change (mean  $\pm$  sem) in expression  
 655 of the indicated transcription factor relative to Th0 culture of the normal control. (E) expression  
 656 of *RORC* was determined by QPCR. Data represent the mean and SEM of 2 - 3 normal donors  
 657 and DOCK8-deficient patients. (F) Memory CD4<sup>+</sup> T cells from healthy donors or DOCK8-  
 658 deficient patients (n=2) were cultured with TAE beads at a cell:bead ratio of 2:1 and 0.5:1, and  
 659 expression of ICOS, CD25, CD69 and CD95 was determined prior to culture (day 0) and 3 days  
 660 after activation. The values represent the mean  $\pm$  sem of the MFI of each of the indicated  
 661 surface receptors. Statistics performed with Prism using two-way ANOVA.

662  
663 **Figure 5: IgE in DOCK8 deficient patients is specific for staple foods and not other Ags**  
664 **such as house dust mites.**

665 Plasma from normal donors and DOCK8-deficient patients was analysed for IgE specific for  
666 (A) a staple food mix (egg white, milk, codfish, wheat, peanut and soyabean) and (B) a house  
667 dust mite mix by ImmunoCAP. The data represent the mean  $\pm$  SEM of 13 normal donors and  
668 15 DOCK8-deficient patients. The dotted line refers to the upper limit of the negative reference  
669 interval (0.35 kUA/L).

670



671 **REFERENCES**

- 672 1. Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al.  
673 Combined immunodeficiency associated with DOCK8 mutations. *N Engl J*  
674 *Med*, 2009:2046-55.
- 675 2. Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, Lopez-Herrera  
676 G, et al. Large deletions and point mutations involving the dedicator of  
677 cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE  
678 syndrome. *J Allergy Clin Immunol* 2009; 124:1289-302.e4.
- 679 3. Su HC, Jing H, Zhang Q. DOCK8 deficiency. *Annals of the New York*  
680 *Academy of Sciences*, 2011:26-33.
- 681 4. Dasouki M, Okonkwo KC, Ray A, Folmsbeel CK, Gozales D, Keles S, et al.  
682 Deficient T Cell Receptor Excision Circles (TRECs) in autosomal recessive  
683 hyper IgE syndrome caused by DOCK8 mutation: implications for  
684 pathogenesis and potential detection by newborn screening. *Clin Immunol*,  
685 2011:128-32.
- 686 5. Jabara HH, McDonald DR, Janssen E, Massaad MJ, Ramesh N, Borzutzky A,  
687 et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B  
688 cell activation. *Nature Immunology*, 2012:612-20.
- 689 6. Ruusala A, Aspenström P. Isolation and characterisation of DOCK8, a  
690 member of the DOCK180-related regulators of cell morphology. *FEBS Lett*,  
691 2004:159-66.
- 692 7. Tybulewicz VLJ, Henderson RB. Rho family GTPases and their regulators in  
693 lymphocytes. *Nat Rev Immunol*, 2009:630-44.
- 694 8. Côté J-F, Vuori K. GEF what? Dock180 and related proteins help Rac to  
695 polarize cells in new ways. *Trends in Cell Biology*, 2007:383-93.
- 696 9. Bittner TC, Pannicke U, Renner ED, Notheis G, Hoffmann F, Belohradsky  
697 BH, et al. Successful long-term correction of autosomal recessive hyper-IgE  
698 syndrome due to DOCK8 deficiency by hematopoietic stem cell  
699 transplantation. *Klin Padiatr*, 2010:351-5.
- 700 10. Boztug H, Karitnig-Weiß C, Ausserer B, Renner ED, Albert MH, Sawalle-  
701 Belohradsky J, et al. Clinical and immunological correction of DOCK8  
702 deficiency by allogeneic hematopoietic stem cell transplantation following a  
703 reduced toxicity conditioning regimen. *Pediatr Hematol Oncol*, 2012:585-94.
- 704 11. Barlogis V, Galambrun C, Chambost H, Lamoureux-Toth S, Petit P, Stephan  
705 J-L, et al. Successful allogeneic hematopoietic stem cell transplantation for  
706 DOCK8 deficiency. *J Allergy Clin Immunol*, 2011:420-22.e2.
- 707 12. Gatz SA, Benninghoff U, Schütz C, Schulz A, Hönig M, Pannicke U, et al.  
708 Curative treatment of autosomal-recessive hyper-IgE syndrome by  
709 hematopoietic cell transplantation. *Bone Marrow Transplant*, 2011:552-6.
- 710 13. Metin A, Tavil B, Azık F, Azkur D, Ok-Bozkaya I, Kocabas C, et al.  
711 Successful bone marrow transplantation for DOCK8 deficient hyper IgE  
712 syndrome. *Pediatr Transplant*, 2012:398-9.
- 713 14. Azık F, Azkur D, Avcı Z, Vezir E, Işık P, Tunç B, et al. Resolution of food-  
714 induced anaphylaxis in DOCK8-deficient patients following bone marrow  
715 transplantation. *Turk J Padiatr*, 2015:112-5.
- 716 15. Happel CS, Stone KD, Freeman AF, Shah NN, Wang A, Lyons JJ, et al. Food  
717 Allergies Can Persist After Myeloablative Hematopoietic Stem Cell  
718 Transplantation in DOCK8-Deficient Patients. *J Allergy Clin Immunol* 2016.

- 719 16. Janssen E, Tsitsikov E, Al-Herz W, Lefranc G, Megarbane A, Dasouki M, et  
720 al. Flow cytometry biomarkers distinguish DOCK8 deficiency from severe  
721 atopic dermatitis. *Clin Immunol*, 2014:220-4.
- 722 17. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, et al. B  
723 cell-intrinsic signaling through IL-21 receptor and STAT3 is required for  
724 establishing long-lived antibody responses in humans. *J Exp Med* 2010;  
725 207:155-71.
- 726 18. Deenick EK, Avery DT, Chan A, Berglund LJ, Ives ML, Moens L, et al.  
727 Naive and memory human B cells have distinct requirements for STAT3  
728 activation to differentiate into antibody-secreting plasma cells. *J Exp Med*  
729 2013; 210:2739-53.
- 730 19. Berglund LJ, Avery DT, Ma CS, Moens L, Deenick EK, Bustamante J, et al.  
731 IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to  
732 enhance their differentiation into plasmablasts. *Blood* 2013; 122:3940-50.
- 733 20. Ma CS, Wong N, Rao G, Avery DT, Torpy J, Hambridge T, et al. Monogenic  
734 mutations differentially affect the quantity and quality of T follicular helper  
735 cells in patients with human primary immunodeficiencies. *J Allergy Clin*  
736 *Immunol* 2015.
- 737 21. Janssen E, Morbach H, Ullas S, Bannock JM, Massad C, Menard L, et al.  
738 Deducator of cytokinesis 8-deficient patients have a breakdown in peripheral  
739 B-cell tolerance and defective regulatory T cells. *J Allergy Clin Immunol*,  
740 2014:1365-74.
- 741 22. Randall KL, Chan SS-Y, Ma CS, Fung I, Mei Y, Yabas M, et al. DOCK8  
742 deficiency impairs CD8 T cell survival and function in humans and mice. *J*  
743 *Exp Med*, 2011:2305-20.
- 744 23. Zhang Q, Dove CG, Hor JL, Murdock HM, Strauss-Albee DM, Garcia JA, et  
745 al. DOCK8 regulates lymphocyte shape integrity for skin antiviral immunity. *J*  
746 *Exp Med*, 2014.
- 747 24. Mizesko MC, Banerjee PP, Monaco-Shawver L, Mace EM, Bernal WE,  
748 Sawalle-Belohradsky J, et al. Defective actin accumulation impairs human  
749 natural killer cell function in patients with dedicator of cytokinesis 8  
750 deficiency. *Journal of Allergy and Clinical Immunology*, 2013:1-9.
- 751 25. Crawford G, Enders A, Gileadi U, Stankovic S, Zhang Q, Lambe T, et al.  
752 DOCK8 is critical for the survival and function of NKT cells. *Blood*,  
753 2013:2052-61.
- 754 26. Ma CS, Avery DT, Chan A, Batten M, Bustamante J, Boisson-Dupuis S, et al.  
755 Functional STAT3 deficiency compromises the generation of human T  
756 follicular helper cells. *Blood* 2012; 119:3997-4008.
- 757 27. Ma CS, Hare NJ, Nichols KE, Dupré L, Andolfi G, Roncarolo M-G, et al.  
758 Impaired humoral immunity in X-linked lymphoproliferative disease is  
759 associated with defective IL-10 production by CD4+ T cells. *J Clin Invest*  
760 2005; 115:1049-59.
- 761 28. Ma CS, Chew GYJ, Simpson N, Priyadarshi A, Wong M, Grimbacher B, et al.  
762 Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. *J*  
763 *Exp Med* 2008; 205:1551-7.
- 764 29. Jing H, Zhang Q, Zhang Y, Hill BJ, Dove CG, Gelfand EW, et al. Somatic  
765 reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease  
766 phenotype. *J Allergy Clin Immunol*, 2014:1667-75.

- 767 30. Ma CS, Suryani S, Avery DT, Chan A, Nanan R, Santner-Nanan B, et al.  
768 Early commitment of naïve human CD4<sup>+</sup> T cells to the T follicular helper  
769 (TFH) cell lineage is induced by IL-12. *Immunol Cell Biol* 2009; 87:590-600.
- 770 31. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of  
771 memory T lymphocytes with distinct homing potentials and effector functions.  
772 *Nature*, 1999:708-12.
- 773 32. Morita R, Schmitt N, Bentebibel S-E, Ranganathan R, Bourdery L, Zurawski  
774 G, et al. Human Blood CXCR5(+)CD4(+) T Cells Are Counterparts of T  
775 Follicular Cells and Contain Specific Subsets that Differentially Support  
776 Antibody Secretion. *Immunity*, 2011:108-21.
- 777 33. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et  
778 al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between  
779 human regulatory and activated T cells. *J Exp Med*, 2006:1693-700.
- 780 34. Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM. Human T cells that  
781 are able to produce IL-17 express the chemokine receptor CCR6. *J Immunol*,  
782 2008:214-21.
- 783 35. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M,  
784 Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human  
785 interleukin 17-producing T helper memory cells. *Nat Immunol*, 2007:639-46.
- 786 36. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al.  
787 Phenotypic and functional features of human Th17 cells. *Journal of*  
788 *Experimental Medicine*, 2007:1849-61.
- 789 37. Gett AV, Hodgkin PD. Cell division regulates the T cell cytokine repertoire,  
790 revealing a mechanism underlying immune class regulation. *Proc Natl Acad*  
791 *Sci USA*, 1998:9488-93.
- 792 38. Tangye SG, Ferguson A, Avery DT, Ma CS, Hodgkin PD. Isotype switching  
793 by human B cells is division-associated and regulated by cytokines. *J*  
794 *Immunol*, 2002:4298-306.
- 795 39. Ma CS, Hodgkin PD, Tangye SG. Automatic generation of lymphocyte  
796 heterogeneity: Division-dependent changes in the expression of CD27, CCR7  
797 and CD45 by activated human naïve CD4<sup>+</sup> T cells are independently  
798 regulated. *Immunology and Cell Biology*, 2004:67-74.
- 799 40. Ma CS, Wong N, Rao G, Nguyen A, Avery DT, Payne K, et al. Unique and  
800 shared signaling pathways cooperate to regulate the differentiation of human  
801 CD4<sup>+</sup> T cells into distinct effector subsets. *J Exp Med* 2016; in press.
- 802 41. Parish CR, Liew FY. Immune response to chemically modified flagellin. 3.  
803 Enhanced cell-mediated immunity during high and low zone antibody  
804 tolerance to flagellin. *J Exp Med*, 1972:298-311.
- 805 42. Constant S, Pfeiffer C, Woodard A, Pasqualini T, Bottomly K. Extent of T cell  
806 receptor ligation can determine the functional differentiation of naïve CD4<sup>+</sup> T  
807 cells. *J Exp Med*, 1995:1591-6.
- 808 43. Brandt K, van der Bosch J, Fliegert R, Gehring S. TSST-1 induces Th1 or Th2  
809 differentiation in naïve CD4<sup>+</sup> T cells in a dose- and APC-dependent manner.  
810 *Scand J Immunol*, 2002:572-9.
- 811 44. Altin JA, Tian L, Liston A, Bertram EM, Goodnow CC, Cook MC. Decreased  
812 T-cell receptor signaling through CARD11 differentially compromises  
813 forkhead box protein 3-positive regulatory versus T(H)2 effector cells to cause  
814 allergy. *J Allergy Clin Immunol* 2011; 127:1277-85.e5.

- 815 45. Kastirr I, Crosti M, Maglie S, Paroni M, Steckel B, Moro M, et al. Signal  
816 Strength and Metabolic Requirements Control Cytokine-Induced Th17  
817 Differentiation of Uncommitted Human T Cells. *J Immunol*, 2015:3617-27.
- 818 46. Gomez-Rodriguez J, Sahu N, Handon R, Davidson TS, Anderson SM, Kirby  
819 MR, et al. Differential expression of interleukin-17A and -17F is coupled to T  
820 cell receptor signaling via inducible T cell kinase. *Immunity* 2009; 31:587-97.
- 821 47. Maggi E. The TH1/TH2 paradigm in allergy. *Immunotechnology* 1998; 3:233-  
822 44.
- 823 48. Randall KL, Lambe T, Johnson A, Treanor B, Kucharska E, Domaschewicz H,  
824 et al. Dock8 mutations cripple B cell immunological synapses, germinal  
825 centers and long-lived antibody production. *Nat Immunol*, 2009:1283-91.
- 826 49. Lambe T, Crawford G, Johnson AL, Crockford TL, Bouriez-Jones T, Smyth  
827 AM, et al. DOCK8 is essential for T-cell survival and the maintenance of  
828 CD8+ T-cell memory. *Eur J Immunol*, 2011:3423-35.
- 829 50. Flesch IEA, Randall KL, Hollett NA, Di Law H, Miosge LA, Sontani Y, et al.  
830 Delayed control of herpes simplex virus infection and impaired CD4(+) T-cell  
831 migration to the skin in mouse models of DOCK8 deficiency. *Immunology  
832 and Cell Biology*, 2015:517-21.
- 833 51. Palendira U, Low C, Bell AI, Ma CS, Abbott RJM, Phan TG, et al. Expansion  
834 of somatically reverted memory CD8+ T cells in patients with X-linked  
835 lymphoproliferative disease caused by selective pressure from Epstein-Barr  
836 virus. *J Exp Med* 2012; 209:913-24.
- 837 52. Plunkett FJ, Franzese O, Belaramani LL, Fletcher JM, Gilmour KC, Sharifi R,  
838 et al. The impact of telomere erosion on memory CD8+ T cells in patients  
839 with X-linked lymphoproliferative syndrome. *Mech Ageing Dev* 2005;  
840 126:855-65.
- 841 53. Ives ML, Ma CS, Palendira U, Chan A, Bustamante J, Boisson-Dupuis S, et  
842 al. Signal transducer and activator of transcription 3 (STAT3) mutations  
843 underlying autosomal dominant hyper-IgE syndrome impair human CD8(+)  
844 T-cell memory formation and function. *J Allergy Clin Immunol* 2013;  
845 132:400-11.e9.
- 846 54. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al.  
847 Dominant-activating germline mutations in the gene encoding the PI(3)K  
848 catalytic subunit p110 $\delta$  result in T cell senescence and human  
849 immunodeficiency. *Nature Immunology* 2014; 15:88-97.
- 850 55. Harada Y, Tanaka Y, Terasawa M, Pieczyk M, Habiro K, Katakai T, et al.  
851 DOCK8 is a Cdc42 activator critical for interstitial dendritic cell migration  
852 during immune responses. *Blood*, 2012:4451-61.
- 853 56. Sornasse T, Larenas PV, Davis KA, de Vries JE, Yssel H. Differentiation and  
854 stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T  
855 cells, analyzed at the single-cell level. *J Exp Med*, 1996:473-83.
- 856 57. Okada S, Markle JG, Deenick EK, Mele F, Averbuch D, Lagos M, et al.  
857 IMMUNODEFICIENCIES. Impairment of immunity to *Candida* and  
858 *Mycobacterium* in humans with bi-allelic RORC mutations. *Science*,  
859 2015:606-13.
- 860 58. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al.  
861 Impaired T(H)17 cell differentiation in subjects with autosomal dominant  
862 hyper-IgE syndrome. *Nature* 2008; 452:773-6.

- 863 59. de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M,  
864 et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-  
865 17-producing T cells. *J Exp Med* 2008; 205:1543-50.
- 866 60. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, et al. Chronic  
867 mucocutaneous candidiasis in humans with inborn errors of interleukin-17  
868 immunity. *Science*, 2011:65-8.
- 869 61. Boisson B, Wang C, Pedergnana V, Wu L, Cypowyj S, Rybojad M, et al. An  
870 ACT1 mutation selectively abolishes interleukin-17 responses in humans with  
871 chronic mucocutaneous candidiasis. *Immunity* 2013; 39:676-86.
- 872 62. Ling Y, Cypowyj S, Aytakin C, Galicchio M, Camcioglu Y, Nepesov S, et al.  
873 Inherited IL-17RC deficiency in patients with chronic mucocutaneous  
874 candidiasis. *J Exp Med* 2015; 212:619-31.
- 875 63. Grimbacher B, Holland SM, Puck JM. Hyper-IgE syndromes. *Immunol Rev*,  
876 2005:244-50.
- 877 64. Engelhardt KR, Gertz ME, Keles S, Schäffer AA, Sigmund EC, Glocker C, et  
878 al. The extended clinical phenotype of 64 patients with dedicator of  
879 cytokinesis 8 deficiency. *J Allergy Clin Immunol*, 2015:402-12.
- 880 65. Takatsu K, Nakajima H. IL-5 and eosinophilia. *Current Opinion in*  
881 *Immunology*, 2008:288-94.
- 882 66. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson  
883 JD, et al. Development, cytokine profile and function of human interleukin 17-  
884 producing helper T cells. *Nat Immunol*, 2007:950-7.
- 885 67. Boisson-Dupuis S, Bustamante J, El-Baghdadi J, Camcioglu Y, Parvaneh N,  
886 El Azbaoui S, et al. Inherited and acquired immunodeficiencies underlying  
887 tuberculosis in childhood. *Immunol Rev*, 2015:103-20.
- 888 68. Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, et al. Recurrent  
889 staphylococcal cellulitis and subcutaneous abscesses in a child with  
890 autoantibodies against IL-6. *J Immunol* 2008; 180:647-54.
- 891 69. Moens L, Tangye SG. Cytokine-Mediated Regulation of Plasma Cell  
892 Generation: IL-21 Takes Center Stage. *Front Immunol* 2014; 5:65.
- 893 70. Boos AC, Hagl B, Schlesinger A, Halm BE, Ballenberger N, Pinarci M, et al.  
894 Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-  
895 based sensitization pattern. *Allergy*, 2014:943-53.
- 896 71. Siegel AM, Stone KD, Cruse G, Lawrence MG, Olivera A, Jung M-y, et al.  
897 Diminished allergic disease in patients with STAT3 mutations reveals a role  
898 for STAT3 signaling in mast cell degranulation. *J Allergy Clin Immunol*,  
899 2013:1388-96.
- 900  
901

**Table 1: DOCK8 deficient patients**

<b>DOCK8-deficient patients</b>	<b>Mutation</b>	<b>Gender</b>	<b>Age at study</b>	<b>IgE (IU/ml)</b>	<b>Allergies/atopic disease</b>	<b>Infections</b>	<b>Other</b>
<b>#1</b>	Homozygous 114 kb deletion spanning exons 4 - 26	female	14	4,864 – 10,000	- No known allergies - Eczema - Hypereosinophilia without lymphopenia	Pneumonia, cutaneous lesions and abscesses, fungal infections, lymphadenitis, cheilitis, <i>Chrysosporium parvum</i> .	Chronic diarrhea, rectal prolapse, bronchiectasis, tolerated BCG vaccine. Deceased.
<b>#2</b>	Homozygous A->T; position 70 exon 7; K271X	female	12	10,000	- No known allergies - Eczema	Severe <i>M. contagiosum</i> , pneumonia, meningitis.	
<b>#3</b>	Homozygous 400 kb deletion (totality of DOCK8 + 5' of KANK1)	female	12	>5,000	- Multiple food, environmental, and drug allergies - Severe eczema (lichenification) - Hypereosinophilia (>3000/mm <sup>3</sup> )	Stomatitis, <i>M. contagiosum</i> , respiratory syncytial virus, HSV1, <i>Candida sp.</i> , <i>H. influenza</i> , <i>P. jirovecii</i> .	Abdominal vasculitis, lymphadenopathy, splenomegaly, CD3 <sup>+</sup> lymphopenia. Successful HSCT.
<b>#4</b>	Homozygous 114 kb deletion spanning exons 4 - 26	male	10	1,552	- No known allergies - Eczema - Hypereosinophilia (7800/mm <sup>3</sup> ).	Recurrent otitis media, herpes labialis, HPV, disseminated plain warts, onychomycosis, <i>Salmonella sp.</i>	Arthritis, uveitis, interstitial lung disease, inflammatory bowel disease, mesenteric vasculitis. Tolerated BCG vaccine. Deceased.
<b>#5</b>	Homozygous 114 kb deletion spanning exons 4 - 26	female	12	19,302	- No known allergies - Eosinophilia (5,000/mm <sup>3</sup> ).	Recurrent upper respiratory tract infection, HPV, flat warts, herpetic stomatitis, <i>Giardia lamblia</i> , <i>Salmonella enterica</i> , <i>E. coli</i> .	Uncomplicated chickenpox. Inflammatory bowel disease, abdominal vasculitis, thrombocytosis. Tolerated BCG vaccine. Deceased.
<b>#6</b>	c.3733_3734del AG;	male	12	1,500	- Multiple food allergies (egg, cow's milk)	Methicillin-resistant <i>S. aureus</i> infection, <i>M.</i>	

	p.R1245EfsX5				<ul style="list-style-type: none"> <li>- Peanut sensitised (tolerant)</li> <li>- Environmental allergies (house dust mite, rye grass, bermuda grass).</li> <li>Previous allergic rhinitis</li> <li>- Infrequent episodic asthma (viral induced) in childhood</li> <li>- Eczema</li> </ul>	<i>contagiosum</i> , recurrent otitis media.	
#7	Homozygous deletion 9p24.3 323,819-324,708	female	8	9,196	<ul style="list-style-type: none"> <li>- Food allergies</li> <li>- Diffuse colonic and esophageal eosinophilia</li> <li>- Eczema</li> <li>- Asthma</li> </ul>	CMV, BK virus, chronic <i>Salmonella</i> , recurrent sinopulmonary infections, skin abscesses.	Sclerosing cholangitis.
#8	heterozygous deletions involving exons 22-25 and 3-32	female	14	6,270	<ul style="list-style-type: none"> <li>- Food allergies</li> <li>- Environmental allergies</li> <li>- Rhinitis</li> <li>- Asthma</li> <li>- Allergic conjunctivitis</li> <li>- Eczema</li> </ul>	HPV, <i>M. contagiosum</i> , meningitis, bacteremia, fungal skin infections.	Vasculopathy. Allergic symptoms improved after transplant.
#9	<ul style="list-style-type: none"> <li>• Large heterozygous . deletion (~200kb)</li> <li>• 2bp heterozygous deletion in exon 41 (c.5307-5308 del AC, pL1770fsX1783)</li> </ul>	female	7	>6,000	<ul style="list-style-type: none"> <li>- No known allergies</li> <li>- Severe eczema (lichenification)</li> <li>- Eosinophilia (&gt;3,000/□m3)</li> </ul>	Skin abscesses, <i>M. contagiosum</i> , recurrent respiratory tract infection, chronic otitis, maxillary sinusitis, bronchiectasis, HPV warts, HSV, <i>H. influenza</i> , <i>Salmonella spp.</i>	↑ IgG, ↓ IgM, ↑ IgA, CD4 <sup>+</sup> lymphopenia.
#10	<ul style="list-style-type: none"> <li>• Large heterozygous . deletion (~200kb)</li> </ul>	male	10	>4,400	<ul style="list-style-type: none"> <li>- No known allergies</li> <li>- Moderate eczema</li> <li>- Eosinophilia</li> </ul>	Skin abscess, <i>M. contagiosum</i> , recurrent upper respiratory tract infection, HPV	↑ IgG, ↓ IgM, ↑ IgA, CD4 <sup>+</sup> lymphopenia.

	• 2bp heterozygous deletion in exon 41 (c.5307-5308 del AC, pL1770fsX1783)					disseminated warts, HSV stomatitis, <i>S. aureus</i> , <i>S. pyrogenes</i> .	
#11	heterozygous large deletions one deletion involving the two gene copies of 80kb in 5' part of the gene and a deletion of one copy of 320kb encompassing the 2/3 <sup>rd</sup> of the 3' region of DOCK8 gene and the 5' part of the KANK1 gene	male	13	>1,100	- No known allergies - Severe eczema (lichenification) - Eosinophilia (>700/mm <sup>3</sup> )	Chronic otitis, clavicle osteomyelitis, bronchitis, pneumonia, bronchiectasis, <i>Morganella spp.</i> , <i>P. aeruginosa</i> , <i>Proteus mirabilis</i> , <i>H. influenza</i> , <i>Giardia intestinalis</i> .	Sclerosing cholangitis, ↑ IgA, ↓ IgM, lymphopenia. Died of post-HSCT complications.
#12	splice site mutation (exon 11) > frame shift, homozygous	male	17	17,045	- Food allergies (pork, peanut, chocolate, dairy, egg) - Severe eczema	Chronic cutaneous and ocular HSV, <i>M. contagiosum</i> , warts, <i>S. aureus</i> skin infections, cutaneous dermatophyte infection.	Chronic liver disease with vanishing bile ducts on biopsy of unclear etiology. Calcified dilated aorta.
#13	Exon 41: c5182C>T homozygous p.R1728X.	male	3	24,893	- Food allergies (milk, egg, tree nuts, peanut) - Severe eczema - Asthma	<i>S. aureus</i> skin infections, Herpetic keratitis, warts, onychomycosis, bacterial, viral and Pneumocystis pneumonia.	



#14	Large deletion + stop codon (exon 11)	male	16	51,010	- Eczema - Asthma	Sinopulmonary infections, <i>Neisseria meningitides</i> arthritis, <i>M. contagiosum</i> and warts.	
#15	Unknown (lack DOCK8 protein; see Supplementary Fig 1)	male	5	17,300	- Food allergies (milk, egg, cashew, pistachio, almond, beef, lamb) - Eczema - Asthma - Bronchiectasis	HSV, <i>S. pyrogenes</i> , <i>H. influenzae</i> , <i>C. albicans</i> , Adenovirus, Norovirus, HHV6, EBV, CMV, VZV, <i>Aspergillus Niger</i> , <i>Cladosporium</i> .	
#16	Unknown (lack DOCK8 protein; see Supplementary Fig 1)	female	4	8,100	- Food allergies (egg, milk, macadamia) - Environmental allergies (house dust mites) - Eczema - Asthma - Allergic rhinitis	Ocular herpes, recurrent lower respiratory tract infection, chronic ear infections.	Bell's Palsy.
#17	Homozygous deletion spanning exon 15-48	female	4	2,294	- Food allergies (peanut cashew, pistachio, sesame) - Sensitization to walnut and egg - Drug allergy (Propofol) - Mild Eczema	Cryptosporidial cholangitis, chronic adenoviral carriage, mild <i>M. contagiosum</i> , <i>Giardia</i> , non-typhi <i>Salmonella</i> , low level CMV viraemia, otitis externa.	
#18	c.12114A>G: p. K405R	female	18,	>10,000	- Food allergies (beans, beef, chicken, cow's milk, egg, fish, peanut, pork, tree nuts, tomato) - Environmental allergies (dust, dog, grasses, mold) - Drug allergies (Cefipime, Lactinex, Propofol) - Eczema (herpeticum)	<i>S. aureus</i> , <i>H. influenzae</i> , Cryptococcal meningitis, <i>Acinetobacter baumannii</i> sepsis, HSV keratitis, herpes zoster virus.	Delayed puberty. Deceased.


#19	Homozygous for a deletion of Exons 28-35	female	17	8,031	- Food allergies (lentils) - Severe eczema	Chronic oral HSV, sinopulmonary infections, onychomycosis and thrush, <i>S. aureus</i> skin infections.	
#20	Homozygous nonsense mutations Exon19: c.2044G>T, p.E682X	female	11	6,690	- Food allergies eggs, milk, nuts, soy, wheat) - Severe eczema	<i>S. aureus</i> skin infections, HSV keratitis.	
#21	Large deletion (exon 21 to end of gene) + small indel with frameshift mutation (exon 12)	male	25	1,162	- Food allergies (nuts) - Eczema	HSV keratitis, sinopulmonary infections, extensive warts.	Squamous cell carcinoma pre-HSCT.
#22	Large deletion (exon 21 to end of gene) + small indel with frameshift mutation (exon 12)	female	22	39	- No known allergies	Extensive warts, sinopulmonary infections.	Severe bronchiectasis.
#23	Nonsense mutation (exon 17) + small indel with frameshift mutation (exon 36)	female	16	180	- Mild eczema	<i>M. contagiosum</i> , warts, sinopulmonary infections.	EBV-B cell lymphoma.
#24	Large deletion (exons 13 to 26)	male	12	1,563	- Food allergies (tree nuts)	Extensive warts, sinopulmonary	


	+ splicing mutation (intron 5)				- Mild eczema	infections, <i>S. aureus</i> osteomyelitis.	
#25	Large deletion (promoter to exon 17) + nonsense mutation (exon 8)	female	19	5,604	- Food allergies (milk, egg, wheat, nuts) - Asthma - Moderate eczema	Sinopulmonary infections, warts and <i>M. contagiosum</i> , Pneumocystis pneumonia, <i>S. aureus</i> skin infections, mucosal candidiasis.	Burkitt's lymphoma (EBV negative), vasculopathy of mid-aorta with bilateral renal artery stenosis, heart failure, improved post HSCT.
#26	Homozygous deletion of at least exons 4-13	female	9	2	- Asthma, - Mild eczema	Sinopulmonary infections, warts.	
#27	Homozygous deletion of exon 36	female	20	>6,000	- Food allergies (milk, kiwi) - Asthma - Moderate eczema	Sinopulmonary infections, warts, chronic cutaneous HSV.	Cerebral vasculopathy with stroke and aortic vasculopathy.
#28	large homozygous deletion of more than 174 kb affecting most of <i>DOCK8</i> (260876_435190) from intron 1 to exon 39	female	12	1,855-8,460	- Food allergies (egg and lentils) - Eczema - Eosinophilia (1,532/mm <sup>3</sup> )	Diarrhea, upper respiratory infections, recurrent meningoencephalitis, chronic otitis media, esophageal candidiasis, lower urinary tract infection, pyelonephritis (twice), <i>Pseudomonas sp</i> (ear), <i>E. coli</i> .	Failure to thrive (short stature), mild scoliosis, seronegative hepatitis, liver steatosis, mild hepatosplenomegaly, extensive abdominal vasculitis, elevated liver enzymes, ↑IgA ↑ IgG, ↑IgM, CD3 <sup>+</sup> lymphopenia (600/ml).


The following patients were used in these experiments:



- phenotyping (#1-18);
- *ex vivo* cytokine and *in vitro* differentiation (#1, #2, #6, #7, #9, #10, #15, #17, #18);
- plasma IgE (#6, #12, #14, #15, #17, #19-28)

Figure 1









(A) Naive CD4<sup>+</sup> T cells(B) Memory CD4<sup>+</sup> T cells


## (C) TBET



## (D) GATA3



## (E) RORC



## (F)

